Joinn Laboratories(China)Co (603127) - Total Assets
Based on the latest financial reports, Joinn Laboratories(China)Co (603127) holds total assets worth CN¥9.53 Billion CNY (≈ $1.40 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Joinn Laboratories(China)Co (603127) shareholders funds for net asset value and shareholders' equity analysis.
Joinn Laboratories(China)Co - Total Assets Trend (2012–2024)
This chart illustrates how Joinn Laboratories(China)Co's total assets have evolved over time, based on quarterly financial data.
Joinn Laboratories(China)Co - Asset Composition Analysis
Current Asset Composition (December 2024)
Joinn Laboratories(China)Co's total assets of CN¥9.53 Billion consist of 53.6% current assets and 46.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.3% |
| Accounts Receivable | CN¥348.49 Million | 3.7% |
| Inventory | CN¥1.48 Billion | 15.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥298.51 Million | 3.2% |
| Goodwill | CN¥138.04 Million | 1.5% |
Asset Composition Trend (2012–2024)
This chart illustrates how Joinn Laboratories(China)Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 603127 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Joinn Laboratories(China)Co's current assets represent 53.6% of total assets in 2024, an increase from 17.6% in 2012.
- Cash Position: Cash and equivalents constituted 10.3% of total assets in 2024, down from 10.8% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 11.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 15.7% of total assets.
Joinn Laboratories(China)Co Competitors by Total Assets
Key competitors of Joinn Laboratories(China)Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Clinica Baviera
MC:CBAV
|
Spain | €228.01 Million |
|
Centro de Imagem Diagnósticos S.A
SA:AALR3
|
Brazil | R$3.03 Billion |
|
Inoviq Ltd
AU:IIQ
|
Australia | AU$24.52 Million |
|
Predilife
PA:ALPRE
|
France | €1.31 Million |
|
Imagion Biosystems Ltd
AU:IBX
|
Australia | AU$932.48K |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
Joinn Laboratories(China)Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.35 | 4.11 | 1.56 |
| Quick Ratio | 3.06 | 2.85 | 1.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥4.09 Billion | CN¥4.04 Billion | CN¥422.87 Million |
Joinn Laboratories(China)Co - Advanced Valuation Insights
This section examines the relationship between Joinn Laboratories(China)Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.33 |
| Latest Market Cap to Assets Ratio | 0.38 |
| Asset Growth Rate (YoY) | -6.3% |
| Total Assets | CN¥9.40 Billion |
| Market Capitalization | $3.56 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Joinn Laboratories(China)Co's assets below their book value (0.38x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Joinn Laboratories(China)Co's assets decreased by 6.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Joinn Laboratories(China)Co (2012–2024)
The table below shows the annual total assets of Joinn Laboratories(China)Co from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥9.40 Billion ≈ $1.37 Billion |
-6.29% |
| 2023-12-31 | CN¥10.03 Billion ≈ $1.47 Billion |
-3.25% |
| 2022-12-31 | CN¥10.36 Billion ≈ $1.52 Billion |
+21.40% |
| 2021-12-31 | CN¥8.54 Billion ≈ $1.25 Billion |
+305.02% |
| 2020-12-31 | CN¥2.11 Billion ≈ $308.44 Million |
+48.66% |
| 2019-12-31 | CN¥1.42 Billion ≈ $207.47 Million |
+24.22% |
| 2018-12-31 | CN¥1.14 Billion ≈ $167.02 Million |
+21.31% |
| 2017-12-31 | CN¥940.87 Million ≈ $137.68 Million |
+57.58% |
| 2016-12-31 | CN¥597.06 Million ≈ $87.37 Million |
+23.88% |
| 2015-12-31 | CN¥481.99 Million ≈ $70.53 Million |
+6.70% |
| 2014-12-31 | CN¥451.71 Million ≈ $66.10 Million |
+18.84% |
| 2013-12-31 | CN¥380.10 Million ≈ $55.62 Million |
+0.01% |
| 2012-12-31 | CN¥380.06 Million ≈ $55.61 Million |
-- |
About Joinn Laboratories(China)Co
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics… Read more